Argenx Se ADR ARGX

$825.61 +6.47 (0.79%)

Valuation

Market cap
51,246,220,000
Revenue TTM
$4,248,050,000
Net income TTM
$1,292,040,000
PE ratio
32.50
Forward PE
29.48
Profit margin
30.41%
Debt to equity
0.00

Trading

Volume
394,700
Avg volume
342,274
Day's range
$814.41 – $828.69
Shares out
62,561,000
Stochastic %K
24%
Beta
0.44
Analysts
Strong Sell
Price target
$1,170.10

Price

Company profile

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for t...

Show more

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave's disease, myositis, Sjögren's disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases; OncoVerity, Inc for cusatuzumab; and AbbVie, Inc. for ARGX-115. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Industry
Biotechnology
Sector
Healthcare
Phone
31 10 703 8441
Website
https://argenx.com
Address
Laarderhoogtweg 25, Amsterdam, Netherlands

Latest news

Stocktwits

moneybag888 Oct 20, 11:48 AM
$ARGX #believe #befirst #alwayshedge
0 replies
Rayvio_News_Filter Oct 19, 12:04 PM
$ARGX 🏥 argenx SE reports new Phase 3 ALKIVIA results showing efgartigimod provided clinically meaningful improvements in immune-mediated necrotizing myopathy and dermatomyositis, with improvements observed as early as Week 4 and sustained through 52 weeks. Curated for market relevance More market highlights: https://rayvio.app/dashboard/?utm_source=lifatpt
0 replies
ericgeurden Oct 19, 5:47 AM
argenx $ARGX fell 16% in one day on Oct 8. Its Q2 sales were up 60%. Cause: a Phase 3 Sjögren's study stopped for futility Close Fri: €727.60 Q2 sales: $1.52B P/E 32 | fwd 25 Q3 results: Thu Oct 22 One setback, or a dent in the growth story? NFA #EuropeanStocks
0 replies
Cache_Money Oct 15, 8:48 PM
$ARGX 👇Easy call
0 replies
stockpicker63 Oct 14, 5:40 PM
$AXSM — Axsome Therapeutics Technical Analysis: AXSM is attempting a rebound after a heavy decline. The stock dropped 5.83% on October 13 on more than 1.2M shares, then recovered strongly today, trading above $161. The first important test is $163–$166. A breakout above $166.50 with strong volume would improve the short-term structure and could trigger a move toward $170–$174. The AI setup is interesting because the stock is bouncing from a heavily sold area, but confirmation is essential. 🤖 AI View: Bullish Reversal Attempt 🎯 SST Score: 78/100 — BULLISH Potential setup: Entry: $161–$164 after confirmation Target 1: $170 Target 2: $174–$177 Stop: Below $155 AI signal: 🟢 BULLISH REVERSAL — volume confirmation required 📈 $ARGX — argenx
0 replies
stockpicker63 Oct 14, 5:33 PM
🚀 STOCKS TO WATCH TODAY! 🚀 🔥 4 STOCKS ON OUR RADAR 📈 $AZN – AstraZeneca A major pharmaceutical player with strong long-term growth potential. Keep an eye on bullish momentum and a possible continuation move. 📈 $AXSM – Axsome Therapeutics An interesting biotech growth stock. Watch for increasing volume, momentum expansion and a potential breakout. 📈 $ARGX – argenx A strong player in the biotech sector. Monitor price action for renewed buying pressure and a possible bullish continuation. 📈 $AZN | $AXSM | $ARGX 🎯 SST Trading Strategy: We focus on short-term swing trading opportunities, targeting potential moves over the next 3–5 trading days. ✅ Watch for strong BUY signals ✅ Confirm momentum with volume ✅ Identify breakout opportunities ✅ Always manage risk with a stop-loss Structure, not emotion. Trade smart with SST! 🐂 #StocksToWatch #StockMarket #SwingTrading #DayTrading #StockSignals #BiotechStocks #AstraZeneca #AXSM #ARGX #SST
0 replies
Quantumup Oct 13, 11:33 AM
Canaccord Genuity y'day⬆️ $TRAX's PT to $60 from $50 and reiterated Buy after First Tracks Biotherapeutics announced positive topline data from the Phase Ib trial in celiac disease (CeD). $ENTO $ARGX TEVA TAK SNY CHGCY IMUX EPRX PHAT AZN BMY Canaccord Genuity said -- The readout included data from Cohort I, which was designed to assess the ability of ANB033 to prevent mucosal damage induced from gluten challenge. The data reported today were positive and statistically significant on both histological measures like villous height-to-crypt depth ratio (VHCD) and intraepithelial lymphocytes (IEL) density and also on patient reported symptoms. We reiterate our BUY rating and increase our 12-month PT to $60 to reflect an increased probability estimate of approval for ANB033 in CeD.
0 replies
Merlintrader Oct 11, 9:38 AM
FcRn Catalysts: $IMVT vs $ARGX $JNJ $UCBJY Immunovant, argenx, Johnson & Johnson and UCB compete across an FcRn landscape where the indication and trial population matter. The comparison examines gMG, Graves disease, clinical setbacks, approved benchmarks and upcoming evidence. UCBJY trades OTC in the US. Full comparative research: https://www.merlintrader.com/imvt-argx-jnj-ucbjy-fcrn-catalyst-comparison/
0 replies